NCT05746104

Second Window Indocyanine Green for All Nervous System Tumors

Enrolling by Invitation
PHASE1Ages 18+Interventional
Abramson Cancer Center at Penn Medicine
~105 participants
Updated 2026-01-22 on ClinicalTrials.gov
What's tested:Administration of Indocyanine Green (ICG) and Visualization of Tumor

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Tumor NIR Signal Compared to Background Brain Normal Signal (SBR)
Measured over Surgery
+2 more outcomes measured
Nervous System Tumor
1 sites across 1 states
Pennsylvania1

This trial hasn't published a contact. View it on ClinicalTrials.gov

  • Tumor NIR Signal Compared to Background Brain Normal Signal (SBR)Surgery

    SBR analysis will be stratified by histology, and the dosing and timing flowchart will be used to achieve optimal SBR.

  • NIR EfficiencySurgery

    After examining the "equivocal tissue" with white light and NIR imaging, a per person success will be recorded, if least one additional specimen is resected using NIR. NIR will be considered efficacious, if significantly more than 10% of patients meet the success criteria. Each histology will be tested separately.

  • NIR True Positive RateSurgery

    Of the additionally resected specimens using NIR, we will find the true positive rate based on pathology. The entire sample will be evaluated jointly; then, each histology will be evaluated separately as there may be multiple specimens per patient surgery. NIR will be considered efficacious if the true positive rate is significantly greater than 50%.